AstraZeneca plc (ADR) (AZN): This Pharma Company Is Making the Right Moves

For AstraZeneca, its Omthera acquisition shall further bolster the company’s product portfolio addressing cardiovascular conditions. In the immediate horizon is Omthera Pharmaceuticals Inc (NASDAQ:OMTH)’s fish oil-based treatment, Epanova, for which late-stage testing has been completed and will be submitted to U.S. regulators’ approval by middle of the year.

In addition to cardiovascular remedies, AstraZeneca plc (ADR) (NYSE:AZN) also derives revenue from its drugs addressing gastrointestinal,  respiratory, autoimmune, metabolic, infection, inflammation, oncology,  and neuro diseases. This diverse portfolio is matched by its extensive global footprint which covers not only Europe, but also the Americas and Asia-Pacific.

Wrap up

Income investors, to wrap it all up, will likely tilt in favor of AstraZeneca compared to Bristol-Myers valuation-wise. The latter’s current trailing 12-month P/E ratio of 55 looks too steep, tempting though it maybe considering Bristol-Myers’ annualized dividend of $1.40 and current yield of 2.95%. In comparison, AstraZeneca has an 11.81 P/E ratio, a $3.80 annualized dividend, and a 7.29% current yield.

The article This Pharma Company Is Making the Right Moves originally appeared on Fool.com and is written by Arturo Cuevas.

Arturo Cuevas has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Arturo is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.